BCL2 and breast carcinoma: Further, bigger association studies, involving our studied markers herein (p53, BCL-2 and Ki-67), PR, ER and HER2 are thus warranted, to elucidate their association with BC treatment outcome and/or prognosis in Tanzanian breast cancer patients.